| QT prolongation alerts lead to monitoring but rarely to therapeutic changes : a prospective hospital study | Frontiers in pharmacology |  | | 2026 | 27 | 61 |
|
| Recurrent serotonin syndrome during low-dose venlafaxine treatment in a patient with reduced CYP2D6 activity | BMJ case reports | | | 2026 | 5 | 3 |
|
| Stimulant drugs and stimulant use disorder | Anesthesiology clinics |  | | 2024 | 80 | 0 |
|
| A genome-wide Association study of the Count of Codeine prescriptions | Scientific reports | | | 2024 | 14 | 109 |
|
| Polygenic risk scores in pharmacogenomics : opportunities and challenges-a mini review | Frontiers in genetics | | | 2023 | 121 | 198 |
|
| Key use cases for artificial intelligence to reduce the frequency of adverse drug events: a scoping review | The Lancet. Digital health | | | 2022 | 164 | 485 |
|
| Intelligent Telehealth in Pharmacovigilance: A Future Perspective | Drug safety | | | 2022 | 197 | 390 |
|
| The Swiss Cheese Prescribing Model for Precision Medicine | American Journal of Medicine | | | 2020 | 325 | 315 |
|
| Stratification du risque basée sur les biomarqueurs dans l'embolie pulmonaire non massive chez les patients âgés d'au moins 65 ans | | | | 2020 | 562 | 658 |
|
| High-sensitive cardiac troponin T as a marker of hemorrhagic complications in elderly patients anticoagulated for non-massive pulmonary embolism | Thrombosis Research | | | 2019 | 385 | 0 |
|
| Comparison of Cardiac and Non-Cardiac Biomarkers for Risk Stratification in Elderly Patients with Non-Massive Pulmonary Embolism | PloS one | | | 2016 | 807 | 412 |
|
